Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab combinations in metastatic renal cell carcinoma
NCT02819596Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- May 2016
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in clear cell renal cell carcinoma (ccRCC) and renal cell carcinoma (RCC), sponsored by Queen Mary University of London. Started May 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02819596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819596.